Season 2, Episode 16
The World’s First Fully Automated, Quantitative, Stain-Free Imaging System
This episode's guest:
Dr. Gideon Ho, PhD
This episode of Digital Pathology Today™ our guest is Dr. Gideon Ho, who co-founded HistoIndex to develop and commercialize the world’s first fully automated, quantitative, stain-free imaging system.
Imagine a world without staining… In the excitement of digital pathology we often forget that we're using with a legacy system of staining tissue pink and purple, which is time-consuming and tissue-destructive. There's got to be a better way.
Under Dr. Ho's direction as the CEO, the laser-based stain-free imaging system has been successfully implemented in academic, clinical and commercial research centers in major universities, hospitals and research facilities around the world. Dr. Ho has multiple patents and journal publications in medical imaging, lasers and optics to his credit.
We’re going to discuss the promise of stain-free digital pathology and some of the technologies developed at Histoindex. What is multiphoton technology? What is second harmonic generation (SHG)? The clinical applications Histoindex is focusing on first is NASH – nonalcoholic steatohepatitis. What is NASH? What is the unmet need? How does it affect society? What are the diagnostic challenges?
More About Dr. Gideon Ho, PhD
Dr. Gideon Ho, Ph. D.
Co-founder and Chief Executive Officer (CEO),
HistoIndex
In 2010, Gideon co-founded HistoIndex as a spin-off from the Agency for Science, Technology and Research (A*STAR), to develop and commercialize the world’s first fully automated, quantitative, stain-free imaging system and gain a first-mover advantage in global healthcare markets. Under his direction as the CEO, the laser-based stain-free imaging system was successfully implemented in academic, clinical and commercial research in major universities, hospitals and contract reference facilities around the world. Gideon has multiple patents and journal publications in medical imaging, lasers and optics to his credits.
As the CEO of HistoIndex, Gideon drives the global business growth and market shares with technological, commercial and marketing strategies, particularly in the United States, and countries in Europe and Asia-Pacific. In addition, he oversees HistoIndex’s ongoing expansion into emerging markets by establishing partnerships with medical and academic institutions with the adoption of the company’s AI-based digital pathology platform on the accurate assessment of treatment efficacy in fibrosis and oncology. Thus far, he has successfully established:
• Nonalcoholic Steatohepatitis (NASH) clinical trials partnerships with multiple pharmaceutical & biotech organizations
• Collaborations on preclinical studies with both industry and academics that covers multiple fibrotic animal models in various organs
• Collaborations on clinical studies with hospitals, universities and research institutes in fibrosis and oncology
• Strategic outreach to deliver significant data from current NASH studies and clinical trials that holds clinical and scientific relevance to pharmaceutical and Biotech C-suites, Principal Investigators and Key Opinion Leaders (KOLs).